Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tarix Orphan obtains FDA fast track status for TXA127 to treat DMD
The approval has been granted for TXA127 to reduce skeletal muscle damage and fibrosis, allowing to improve muscle strength in DMD patients. DMD is a genetic disorder that
The approval has been granted for TXA127 to reduce skeletal muscle damage and fibrosis, allowing to improve muscle strength in DMD patients. DMD is a genetic disorder that
A DFU is an open sore that affect the heel, toes, top, or bottom of the foot, which usually starts as a cut and can get bigger over
The company’s lead product candidate, enobosarm, is also being evaluated in a separate Phase II clinical trial to treat estrogen receptor positive (ER+), AR+ breast cancer. The open-label,
The FDA has determined MPI’s Hydroxyprogesterone Caproate Injection USP, 250 mg/ mL (1.25 g/5 mL vials) to be bioequivalent and, therefore, therapeutically equivalent to Delalutin Injection, 250 mg/mL
The trial is a randomized, double blind, active control, multi-center, global study in patients with chronic plaque psoriasis to compare the safety, efficacy and immunogenicity of M923 with
Pharmorphix is an established provider of solid form services, including polymorph studies, salt selection, co-crystallization, chiral separations and process scale up that are critical to successful drug discovery
OTO-311 is a sustained-exposure formulation of potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine. The approval has been granted to commence a Phase I dose escalation clinical safety
Quinsair is an inhaled formulation of levofloxacin, which already received approval in the European Union and Canada. It is used to manage chronic pulmonary infections due to Pseudomonas
SEC alleged that the company’s JV violated the Foreign Corrupt Practices Act (FCPA) and reaped over $11m in profits from this violation. According to the SEC’s order instituting
With the approval, the company now intends to begin the PRTX-100-203 trial at several sites in France with patient enrollment expected to start by this year end. Furthermore,